40
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Provisional focal stenting of complex femoropopliteal lesions using the Multi-LOC multiple stent delivery system – 12-month results from the LOCOMOTIVE EXTENDED study

      research-article

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Summary: Background: This study aimed to evaluate a Multiple Stent Delivery System for provisional focal stenting of the femoropopliteal artery. Patient and methods: The LOCOMOTIVE EXTENDED study (Multi- LOC for fl Ow li Miting Outcomes after plain old balloon angioplasty and/or drug-coated balloon Treatment in the infrainguinal position with the object IVE to implant multiple stent segments) is a prospective, single-arm, multicentre observational study. The Multi-LOC Multiple Stent Delivery System (B.Braun, Melsungen, Germany) was used for provisional focal stenting of the femoropopliteal artery. We enrolled 357 patients with 449 femoropopliteal lesions; all had flow-limiting dissections or recoil following angioplasty. Eligibility included Rutherford classification 2 to 5 with a de novo or non-stented restenotic femoropopliteal lesion undergoing plain balloon or drug-coated balloon angioplasty. The 6- and 12-month efficacy endpoints encompassed target lesion revascularisation and primary patency rates. Results: The mean patient age was 71 ± 10 years. The mean lesion length was 16.0 ± 9.7 cm; 44.5% were TASC II C/D lesions and 31.4% were chronic total occlusions. By operator choice, 45% of the patients underwent drug-coated balloon angioplasty. On average, 4.0 stents (each 13 mm long) were placed in each lesion, resulting in a scaffolding proportion of 56% of the total lesion length with a technical success rate of 98.3%. At 6 and 12 months, the freedom from clinically driven target lesion revascularisation was 95.5% and 88.7% and the primary patency rates were 88.7% and 82.3%, respectively. At 12 months, significant improvements were noted in Rutherford categories and ankle-brachial indices. In multiple regression analyses, both diabetes mellitus and no distal run-off vessel showed a trend toward worse TLR, while other factors such as DCB predilation or the lesion length were not predictive. Conclusions: The LOCOMOTIVE EXTENDED study demonstrated the safety and efficacy of the Multi-LOC stent system for focal provisional stenting of complex femoropopliteal lesions.

          Related collections

          Most cited references44

          • Record: found
          • Abstract: found
          • Article: not found

          Peripheral Artery Disease: Evolving Role of Exercise, Medical Therapy, and Endovascular Options.

          The prevalence of peripheral artery disease (PAD) continues to increase worldwide. It is important to identify patients with PAD because of the increased risk of myocardial infarction, stroke, and cardiovascular death and impaired quality of life because of a profound limitation in exercise performance and the potential to develop critical limb ischemia. Despite effective therapies to lower the cardiovascular risk and prevent progression to critical limb ischemia, patients with PAD continue to be under-recognized and undertreated. The management of PAD patients should include an exercise program, guideline-based medical therapy to lower the cardiovascular risk, and, when revascularization is indicated, an "endovascular first" approach. The indications and strategic choices for endovascular revascularization will vary depending on the clinical severity of the PAD and the anatomic distribution of the disease. In this review, we discuss an evidence-based approach to the management of patients with PAD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            1-Year Results of the ZEPHYR Registry (Zilver PTX for the Femoral Artery and Proximal Popliteal Artery): Predictors of Restenosis.

            This study sought to assess the rate and predictors of 1-year restenosis after drug-eluting stent implantation for femoropopliteal (FP) lesions in patients with peripheral arterial disease.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Does diabetes mellitus play a role in restenosis and patency rates following lower extremity peripheral arterial revascularization? A critical overview.

              Patients with diabetes mellitus (DM) are at increased risk of developing lower extremity peripheral arterial disease (PAD). The effect of DM on restenosis and patency rates in patients with PAD undergoing surgical revascularization or percutaneous interventions has not been fully clarified. We therefore critically reviewed the role of DM in restenosis, as well as primary and secondary patency rates in these patients. We searched Medline for studies investigating the effect of DM on restenosis (primary and secondary patency) rates in patients undergoing surgical/percutaneous interventions for the treatment of lower extremity PAD. Search terms used were "diabetes and peripheral arterial disease," "angioplasty," "restenosis," "revascularization," "patency rates," and "in-stent restenosis." Diabetic patients with PAD have similar restenosis, primary patency, and secondary patency rates compared with nondiabetic patients. However, mortality and amputation rates are increased in patients with DM. This increased risk of mortality and amputation may distort the estimation of restenosis and patency rates. Strict glucose control should be implemented in diabetic patients. Additionally, the use of antiplatelet agents and statins may have a beneficial effect on restenosis and patency rates. The role of radiation therapy in preventing restenosis remains to be determined. Patients with PAD and DM should receive optimal medical therapy to improve cardiovascular outcome and decrease functional decline. The direct involvement of vascular surgeons in the management of PAD patients is essential to reduce the incidence of cardiovascular events and mortality rates.
                Bookmark

                Author and article information

                Contributors
                Journal
                vas
                VASA
                European Journal of Vascular Medicine
                Hogrefe AG, Bern
                0301-1526
                1664-2872
                November 26, 2020
                : 50
                : 3
                : 209-216
                Affiliations
                [ 1 ]Department of Angiology, Cardiology and Diabetes associated diseases, Diakonissenkrankenhaus Mannheim, Gefäßzentrum Oberrhein, Mannheim, Germany
                [ 2 ]Universitäts-Herzzentrum Freiburg, Bad Krozingen GmbH, Bad Krozingen, Germany
                [ 3 ]Centrum Kardiologii Józefów, American Heart of Poland, Józefów, Poland
                [ 4 ]Nuovo Ospedale San Giovanni di Dio, Firenze, Italy
                [ 5 ]Medical Scientific Affairs, B.Braun Melsungen AG, Berlin, Germany
                [ 6 ]Department of Internal Medicine and Cardiology, Charité – Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany
                [ 7 ]Department of Angiology, Sankt-Gertrauden-Krankenhaus, Berlin, Germany
                [ 8 ]Asklepios Klinikum Hamburg Harburg, Hamburg, Germany
                [ 9 ]Heinrich-Braun-Klinikum, Zwickau, Germany
                [ 10 ]University Hospital Center Sisters of Mercy, Zagreb, Croatia
                [ 11 ]University Hospital Merkur, Zagreb, Croatia
                [ 12 ]Evangelisches Krankenhaus Mülheim, Mühlheim, Germany
                [ 13 ]Klinik Kösching, Kösching, Germany
                [ 14 ]First Department of Medicine, Faculty of Medicine, University Medical Centre Mannheim (UMM), University of Heidelberg, Mannheim, Germany
                Author notes
                Martin Sigl, MD, First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany, E-mail martin.sigl@ 123456umm.de
                Author information
                https://orcid.org/0000-0001-6162-6304
                Article
                vas_50_3_209
                10.1024/0301-1526/a000927
                fe397498-586c-4442-aebd-fa445dddbba0
                Distributed as a Hogrefe OpenMind article under the license CC BY 4.0 (https://creativecommons.org/licenses/by/4.0)

                Distributed as a Hogrefe OpenMind article under the license CC BY 4.0 ( https://creativecommons.org/licenses/by/4.0)

                History
                : October 6, 2020
                : November 4, 2020
                Funding
                Funding: This study was funded by B. Braun on a milestone basis per included patient and available follow-ups at 6 and 12 months .
                Categories
                Original communication

                Medicine
                multiple stent delivery system,Femoropopliteal lesions,spot stenting,target lesion revascularisation,patency

                Comments

                Comment on this article